Actively Recruiting
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
Led by University of Florida · Updated on 2025-12-26
450
Participants Needed
1
Research Sites
273 weeks
Total Duration
On this page
Sponsors
U
University of Florida
Lead Sponsor
N
National Institute of General Medical Sciences (NIGMS)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Adverse outcomes in surgical sepsis patients are secondary to dysregulated emergency myelopoiesis, and expansion of myeloid-derived suppressor cells. Here we propose to determine the underlying mechanisms behind the increased expansion of these leukocyte populations and the underlying mechanisms that drive inflammation and immune suppression.
CONDITIONS
Official Title
Dysfunctional Myelopoiesis and Myeloid-Derived Suppressor Cells in Sepsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Meets criteria for sepsis or septic shock by Sepsis-3 consensus criteria
- Adults age 18 years or older with blunt trauma
- Blunt trauma patients with Injury Severity Score (ISS) 25 or higher
- Blunt trauma patients with ISS over 15 and either significant blood transfusion, spine injury, or shock on arrival
- Blunt trauma patients with ISS over 15 and at least two of these: age over 55, chest injury, positive alcohol on arrival, or red blood cell transfusion in first 24 hours
You will not qualify if you...
- Diseases causing significant immune system dysfunction
- Conditions or care goals that prevent recovery after sepsis, including irreversible shock, uncontrollable infection source, futile care, alternative shock diagnoses, low CD4+ count in HIV infection, severe brain injury with Glasgow Coma Score 3
- Known pregnancy
- Enrollment more than 96 hours after suspected sepsis onset
- Pre-hospital bedridden status with WHO/Zubrod score 4 or higher
- Diagnosis after enrollment not consistent with sepsis/septic shock by Sepsis-3 criteria
- Burn injury over 20% of total body surface area
- Patients not expected to survive more than 48 hours
- Prisoners
- Previous bone marrow transplantation
- End Stage Renal Disease
- Pre-existing blood diseases
- Advanced care directives limiting resuscitation
- Known HIV infection with CD4+ count below 200 cells/mm3
- Burn injury greater than 20% total body surface area
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UF Health at Shands hospital
Gainesville, Florida, United States, 32610
Actively Recruiting
Research Team
J
Jennifer Lanz, MSN
CONTACT
R
Ruth Davis, BSN
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here